Travere Licenses Kidney Disease Drug in Billion-Dollar Deal

Travere Therapeutics has significantly expanded its rare kidney disease pipeline through an exclusive licensing and collaboration agreement with Everest Medicines for civorebrutinib, an investigational oral Bruton’s tyrosine kinase (BTK) inhibitor that could potentially become a new treatment option across several immune-mediated kidney disorders.

Under the agreement, Travere will gain exclusive development and commercialization rights to civorebrutinib in all markets outside China and certain countries in East and Southeast Asia. The deal underscores growing industry interest in therapies targeting the underlying immune mechanisms that drive rare kidney diseases, many of which continue to have limited treatment options and poor long-term outcomes.

The financial terms of the transaction include an upfront payment of $112.5 million from Travere to Everest Medicines. In addition, Everest could receive up to approximately $1.03 billion in future clinical, regulatory, and commercial milestone payments across multiple indications. The agreement also includes tiered royalties on future product sales, ranging from high single-digit to double-digit percentages based on annual net sales.

Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to target immune system pathways involved in kidney damage. BTK plays a central role in B-cell receptor signaling and is involved in the activation, maturation, and proliferation of B cells, which produce antibodies that can contribute to autoimmune and inflammatory diseases.

The drug is currently being developed for primary membranous nephropathy (PMN), a rare autoimmune kidney disorder characterized by damage to the kidney’s filtering units. Travere also plans to investigate the therapy in focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), and potentially additional immune-mediated kidney diseases.

Interest in civorebrutinib has grown following encouraging results from a Phase 1/2 clinical trial in patients with PMN. Previously reported data showed rapid and sustained reductions in anti-PLA2R autoantibodies, a key disease marker, along with meaningful decreases in proteinuria, a major indicator of kidney damage. The study also reported high rates of immunologic and clinical remission while maintaining stable kidney function through 52 weeks of follow-up. According to the companies, the treatment has been generally well tolerated throughout clinical development.

Travere believes the therapy has the potential to become a “pipeline-in-a-product” due to its possible application across multiple kidney diseases that share similar immune-mediated mechanisms. These conditions can progressively damage the kidneys, resulting in protein leakage into the urine, declining kidney function, and eventually the need for dialysis or transplantation.

Eric Dube, President and Chief Executive Officer of Travere Therapeutics, described civorebrutinib as a strategic addition to the company’s growing rare kidney disease portfolio. He noted that while progress has been made in diseases such as IgA nephropathy and FSGS, significant unmet medical needs remain. According to Dube, civorebrutinib’s oral administration, reversible mechanism of action, and potential applicability across multiple conditions position it as a promising candidate for transforming treatment approaches in rare kidney diseases.

Everest Medicines Chairman Yifang Wu echoed that view, highlighting the drug’s differentiated profile and encouraging early clinical results. He said the collaboration combines Everest’s development efforts with Travere’s expertise in kidney disease commercialization and global market access, creating an opportunity to accelerate development and expand treatment options for patients worldwide.

The agreement also aligns with Everest’s broader strategy of combining internal research efforts with external partnerships to maximize the value of innovative therapies. For Travere, the deal strengthens its position as a leader in rare kidney diseases and broadens its pipeline beyond existing programs.

If future clinical studies confirm the early promise of civorebrutinib, the therapy could emerge as a significant new treatment option for patients with several serious immune-mediated kidney disorders that currently lack effective long-term therapies.